Carregant...
Caplacizumab: First Global Approval
Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody(®) caplacizumab (Cablivi™) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Based on positive results in phase II and III trials in patients with aTTP, caplacizumab was recently approved in the E...
Guardat en:
| Publicat a: | Drugs |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer International Publishing
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6280848/ https://ncbi.nlm.nih.gov/pubmed/30298461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-018-0989-0 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|